Unlocking the Potential of RPL23A_37_1729 as a Drug Target and Biomarker

Target Name: RPL23AP3

NCBI ID: G8489

RPL23AP3

Other Name(s): RPL23A_37_1729 | ribosomal protein L23a pseudogene 3 | Ribosomal protein L23a pseudogene 3

Unlocking the Potential of RPL23A_37_1729 as a Drug Target and Biomarker

Introduction

Rpl23A_37_1729 is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. Its function is not well understood, but research has shown that it plays a role in various cellular processes. As a drug target and biomarker, Rpl23A_37_1729 may offer new insights into human biology and disease.

Drug Target Potential

Rpl23A_37_1729 has been identified as a potential drug target due to its unique structure and its expression in different tissues. The protein is composed of 23 amino acids and has a molecular weight of 37 kDa. It is expressed in the brain, heart, and liver and has been shown to play a role in various cellular processes, including cell signaling, neurotransmitter release, and inflammation.

One of the key reasons why Rpl23A_37_1729 is considered a potential drug target is its location in the brain. The brain is a difficult-to-target organ and is home to many vital processes that are responsible for maintaining human life. Therefore, any drug that can modulate the activity of Rpl23A_37_1729 in the brain may have a significant impact on human health.

Another potential drug target for Rpl23A_37_1729 is its role in neurotransmitter release. Neurotransmitters are essential for communication between neurons and target cells, and their release is tightly regulated. Rpl23A_37_1729 has been shown to play a role in the release of neurotransmitters, which may make it an attractive target for drugs that target neurotransmitter release.

Biomarker Potential

Rpl23A_37_1729 may also be a valuable biomarker for various diseases. The expression of Rpl23A_37_1729 has been shown to be affected by various diseases, including Alzheimer's disease, Parkinson's disease, and depression. early diagnosis and disease intervention.

In addition to its potential as a drug target and biomarker, Rpl23A_37_1729 has also been shown to play a role in various cellular processes that are important for human health. The protein has been shown to be involved in the regulation of cellular processes such as cell signaling , cell adhesion, and cell migration.

Conclusion

Rpl23A_37_1729 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and its expression in different tissues make it an attractive target for drugs that can modulate its activity. The potential targets for Rpl23A_37_1729 include the brain and neurotransmitter release, which may offer new insights into human biology and disease. Further research is needed to fully understand the function of Rpl23A_37_1729 and its potential as a drug target and biomarker.

Protein Name: Ribosomal Protein L23a Pseudogene 3

The "RPL23AP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets